JP7385602B2 - 肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ - Google Patents

肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ Download PDF

Info

Publication number
JP7385602B2
JP7385602B2 JP2020565840A JP2020565840A JP7385602B2 JP 7385602 B2 JP7385602 B2 JP 7385602B2 JP 2020565840 A JP2020565840 A JP 2020565840A JP 2020565840 A JP2020565840 A JP 2020565840A JP 7385602 B2 JP7385602 B2 JP 7385602B2
Authority
JP
Japan
Prior art keywords
pyrrolo
pharmaceutical composition
butoxy
amine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525260A (ja
Inventor
チャン，シークウァン
ヤン，リン
チャン，イン
チャン，ミンチャン
ソン，ウェイ
シュ，ホンジヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2021525260A publication Critical patent/JP2021525260A/ja
Application granted granted Critical
Publication of JP7385602B2 publication Critical patent/JP7385602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020565840A 2018-05-25 2019-05-24 肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ Active JP7385602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810560770 2018-05-25
CN201810560770.X 2018-05-25
PCT/CN2019/088360 WO2019223788A1 (zh) 2018-05-25 2019-05-24 用于治疗肺癌的tlr7激动剂及其药物组合

Publications (2)

Publication Number Publication Date
JP2021525260A JP2021525260A (ja) 2021-09-24
JP7385602B2 true JP7385602B2 (ja) 2023-11-22

Family

ID=68616579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565840A Active JP7385602B2 (ja) 2018-05-25 2019-05-24 肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ

Country Status (8)

Country Link
US (1) US12128047B2 (de)
EP (1) EP3816166A4 (de)
JP (1) JP7385602B2 (de)
KR (1) KR20210013183A (de)
CN (1) CN112105620B (de)
AU (1) AU2019272478B2 (de)
CA (1) CA3101370A1 (de)
WO (1) WO2019223788A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105620B (zh) 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
CN115119508B (zh) * 2021-01-20 2024-05-24 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
CN119552171A (zh) * 2023-09-04 2025-03-04 浙江养生堂天然药物研究所有限公司 大环吡唑并嘧啶类化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524037A (ja) 2014-08-15 2017-08-24 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｔｌｒ７アゴニストとして使用されるピロロピリミジン化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
EA030603B1 (ru) * 2014-05-01 2018-08-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
BR112018008880B1 (pt) 2015-11-05 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 7-(tiazol-5-il) pirrolopirimidina, seu uso, e composição farmacêutica
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107970241B (zh) * 2018-01-22 2020-05-22 正大天晴药业集团股份有限公司 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
CN112105620B (zh) 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524037A (ja) 2014-08-15 2017-08-24 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｔｌｒ７アゴニストとして使用されるピロロピリミジン化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAN, Baohui et al.，British Journal of Cancer，2018年02月13日，Vol.118，p.654-661
WANG, Chenchen et al.，Oncotarget，2014年12月15日，Vol.6, No.3，p.1779-1789

Also Published As

Publication number Publication date
KR20210013183A (ko) 2021-02-03
CA3101370A1 (en) 2019-11-28
AU2019272478B2 (en) 2024-06-06
US12128047B2 (en) 2024-10-29
JP2021525260A (ja) 2021-09-24
EP3816166A4 (de) 2022-04-06
CN112105620B (zh) 2026-02-24
US20210220362A1 (en) 2021-07-22
WO2019223788A1 (zh) 2019-11-28
EP3816166A1 (de) 2021-05-05
CN112105620A (zh) 2020-12-18
AU2019272478A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
TWI726363B (zh) Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法
WO2025067459A2 (en) Therapies for the treatment of cancer
WO2023190748A1 (ja) 腫瘍治療用医薬組成物
EA023423B1 (ru) Ингибиторы репликации вирусов гриппа
JP7385602B2 (ja) 肺癌を治療するためのｔｌｒ７アゴニストおよびその医薬の組み合わせ
WO2001083456A1 (en) Condensed heteroaryl derivatives
CN116261455B (zh) 一种药物组合物及其在治疗癌症中的用途
NZ554552A (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
CN112839947B (zh) 用于治疗结直肠癌的tlr7激动剂及其药物组合
TW202342003A (zh) 治療卵巢癌之藥物組合及方法
HK40039547A (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
HK40044357A (en) Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
CN120118079B (zh) 一种异喹啉类药物及其在改善或治疗消化道肿瘤中的应用
CN114423433B (zh) 包含tlr7激动剂的药物组合
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途
HK40095032B (zh) 一种药物组合物及其在治疗癌症中的用途
CN115105507A (zh) 帕唑帕尼在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN120390748A (zh) 磷脂酰肌醇3-激酶的新型抑制剂
CN117729922A (zh) Egfr抑制剂的药物组合及其应用
HK40020967B (en) Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150